Seizert Capital Partners’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-66,245
| Closed | -$8.32M | – | 172 |
|
|
2025
Q2 | $8.32M | Buy |
66,245
+15,788
| +31% | +$1.97M | 0.37% | 54 |
|
|
2025
Q1 | $6.9M | Buy |
50,457
+10,786
| +27% | +$1.54M | 0.32% | 56 |
|
|
2024
Q4 | $6.07M | Buy |
39,671
+28,667
| +261% | +$4.84M | 0.27% | 66 |
|
|
2024
Q3 | $2.13M | Buy |
11,004
+3,418
| +45% | +$715K | 0.1% | 109 |
|
|
2024
Q2 | $1.76M | Buy |
7,586
+2,431
| +47% | +$528K | 0.09% | 113 |
|
|
2024
Q1 | $1.11M | Sell |
5,155
-119
| -2% | -$27.9K | 0.05% | 127 |
|
|
2023
Q4 | $1.36M | Buy |
5,274
+126
| +2% | +$30.9K | 0.07% | 122 |
|
|
2023
Q3 | $1.32M | Buy |
5,148
+1,405
| +38% | +$376K | 0.07% | 119 |
|
|
2023
Q2 | $1.07M | Sell |
3,743
-390
| -9% | -$116K | 0.06% | 121 |
|
|
2023
Q1 | $1.15M | Buy |
4,133
+640
| +18% | +$177K | 0.06% | 121 |
|
|
2022
Q4 | $967K | Buy |
+3,493
| New | +$987K | 0.05% | 130 |
|
|
2022
Q1 | – | Sell |
-21,464
| Closed | -$5.15M | – | 204 |
|
|
2021
Q4 | $5.15M | Buy |
21,464
+19,655
| +1,087% | +$5.05M | 0.23% | 72 |
|
|
2021
Q3 | $512K | Sell |
1,809
-64
| -3% | -$21K | 0.02% | 169 |
|
|
2021
Q2 | $649K | Sell |
1,873
-116,059
| -98% | -$35.2M | 0.03% | 168 |
|
|
2021
Q1 | $33M | Buy |
117,932
+3,859
| +3% | +$1.04M | 1.72% | 20 |
|
|
2020
Q4 | $27.9M | Sell |
114,073
-8,221
| -7% | -$2.12M | 1.63% | 24 |
|
|
2020
Q3 | $34.7M | Buy |
122,294
+194
| +0.2% | +$54.1K | 2.28% | 11 |
|
|
2020
Q2 | $32.7M | Buy |
122,100
+9,482
| +8% | +$2.85M | 2.21% | 17 |
|
|
2020
Q1 | $35.6M | Sell |
112,618
-40,509
| -26% | -$12.3M | 2.62% | 10 |
|
|
2019
Q4 | $45.4M | Sell |
153,127
-39,358
| -20% | -$10.9M | 2.26% | 13 |
|
|
2019
Q3 | $44.8M | Buy |
192,485
+5,174
| +3% | +$1.2M | 2.26% | 11 |
|
|
2019
Q2 | $43.8M | Buy |
187,311
+22,764
| +14% | +$5.26M | 2.15% | 17 |
|
|
2019
Q1 | $38.9M | Buy |
164,547
+63,895
| +63% | +$20.1M | 1.74% | 22 |
|
|
2018
Q4 | $30.3M | Sell |
100,652
-4,832
| -5% | -$1.54M | 1.37% | 30 |
|
|
2018
Q3 | $37.3M | Buy |
105,484
+6,929
| +7% | +$2.39M | 1.37% | 28 |
|
|
2018
Q2 | $27M | Hold |
98,555
| – | – | 0.98% | 39 |
|
|
2018
Q1 | $27M | Buy |
98,555
+55
| +0.1% | +$17.1K | 0.98% | 39 |
|
|
2017
Q4 | $31.4M | Sell |
98,500
-755
| -0.8% | -$242K | 1.13% | 38 |
|
|
2017
Q3 | $31.1M | Sell |
99,255
-5,821
| -6% | -$1.72M | 1.14% | 39 |
|
|
2017
Q2 | $28.5M | Sell |
105,076
-2,115
| -2% | -$559K | 1.03% | 43 |
|
|
2017
Q1 | $29.3M | Buy |
107,191
+5,900
| +6% | +$1.67M | 1.04% | 41 |
|
|
2016
Q4 | $28.7M | Buy |
101,291
+3,925
| +4% | +$1.16M | 1.02% | 41 |
|
|
2016
Q3 | $30.5M | Sell |
97,366
-6,796
| -7% | -$2.01M | 1.13% | 38 |
|
|
2016
Q2 | $25.2M | Buy |
104,162
+56,565
| +119% | +$14.9M | 0.96% | 43 |
|
|
2016
Q1 | $12.4M | Buy |
47,597
+17,631
| +59% | +$4.66M | 0.42% | 66 |
|
|
2015
Q4 | $9.18M | Sell |
29,966
-1,298
| -4% | -$373K | 0.29% | 79 |
|
|
2015
Q3 | $9.12M | Buy |
31,264
+26,527
| +560% | +$8.76M | 0.28% | 82 |
|
|
2015
Q2 | $1.91M | Buy |
4,737
+2,763
| +140% | +$1.11M | 0.05% | 148 |
|
|
2015
Q1 | $834K | Sell |
1,974
-61
| -3% | -$24K | 0.02% | 155 |
|
|
2014
Q4 | $691K | Sell |
2,035
-50
| -2% | -$16.2K | 0.01% | 159 |
|
|
2014
Q3 | $690K | Buy |
+2,085
| New | +$687K | 0.01% | 148 |
|
Other funds holding BIIB
Seizert Capital Partners's BIIB Position: Q3 2025 in Review
Seizert Capital Partners sold out of Biogen (BIIB) in Q3 2025, closing a stake of 66,245 shares — an estimated $8.32M sold.
Seizert Capital Partners first reported a position in BIIB in Q3 2014 and held it in 41 quarters. The position peaked at $45.4M in Q4 2019. 906 funds tracked by Wall St. Rank hold BIIB as of Q3 2025.
- Seizert Capital Partners reported no remaining Biogen position as of Q3 2025 after selling out during the quarter.
- Seizert Capital Partners sold 66,245 Biogen shares in Q3 2025, an estimated $8.32M.
- Seizert Capital Partners first reported a position in Biogen in Q3 2014 and held it in 41 quarters.
- Seizert Capital Partners's Biogen position peaked at $45.4M in Q4 2019.
- 906 funds tracked by Wall St. Rank held Biogen as of Q3 2025.
Based on Seizert Capital Partners's 13F filing for Q3 2025, filed 29 Oct 2025.